Guardant Health Guardant360® Liquid Biopsy Blood Test Works For Comprehensive Genomic Profiling In Advanced Lung Cancer
REDWOOD CITY, Ca – Guardant Health, Inc. (Nasdaq: GH) along with leading academic institutions and pharmaceutical companies will present data demonstrating the advantages of using the Guardant360® liquid biopsy test for clinical decision-making in advanced lung cancer at the IASLC 2021 World Conference on Lung Cancer hosted by the International Association for the Study of Lung … Read more